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principle in practice: Guidance on
handling randomisation errors
Lisa N Yelland1,2, Thomas R Sullivan2, Merryn Voysey3, Katherine J Lee4,5,
Jonathan A Cook6,7 and Andrew B Forbes8
Abstract
Background: The intention-to-treat principle states that all randomised participants should be analysed in their rando-
mised group. The implications of this principle are widely discussed in relation to the analysis, but have received limited
attention in the context of handling errors that occur during the randomisation process. The aims of this article are to
(1) demonstrate the potential pitfalls of attempting to correct randomisation errors and (2) provide guidance on handling
common randomisation errors when they are discovered that maintains the goals of the intention-to-treat principle.
Methods: The potential pitfalls of attempting to correct randomisation errors are demonstrated and guidance on
handling common errors is provided, using examples from our own experiences.
Results: We illustrate the problems that can occur when attempts are made to correct randomisation errors and
argue that documenting, rather than correcting these errors, is most consistent with the intention-to-treat principle.
When a participant is randomised using incorrect baseline information, we recommend accepting the randomisation but
recording the correct baseline data. If ineligible participants are inadvertently randomised, we advocate keeping them in
the trial and collecting all relevant data but seeking clinical input to determine their appropriate course of management,
unless they can be excluded in an objective and unbiased manner. When multiple randomisations are performed in error
for the same participant, we suggest retaining the initial randomisation and either disregarding the second randomisation
if only one set of data will be obtained for the participant, or retaining the second randomisation otherwise. When par-
ticipants are issued the incorrect treatment at the time of randomisation, we propose documenting the treatment
received and seeking clinical input regarding the ongoing treatment of the participant.
Conclusion: Randomisation errors are almost inevitable and should be reported in trial publications. The intention-
to-treat principle is useful for guiding responses to randomisation errors when they are discovered.
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Introduction
The intention-to-treat (ITT) principle is widely dis-
cussed in the randomised trials literature.1–13 While the
exact definition of ITT is a matter of considerable
debate, particularly in the presence of missing outcome
data,6,8 ITT is generally taken to mean that all rando-
mised participants should be analysed in their rando-
mised group, irrespective of compliance with the trial
protocol. An ITT analysis is widely accepted as the
gold standard for assessing the superiority of the inter-
vention in randomised trials. It preserves the balance in
prognostic factors achieved by randomisation, which is
important for avoiding selection bias and establishing
causation.2 A popular alternative is to conduct a
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‘modified ITT analysis’, which has been used to
describe a variety of deviations from the standard ITT
approach, such as exclusion of participants who were
found to be ineligible or failed to receive any
treatment.10
Although rarely recognised, the ITT principle has
implications for dealing with errors that occur during
the randomisation process. These include participants
being randomised using incorrect baseline information,
ineligible participants being randomised, multiple ran-
domisations being performed for the same participant,
and participants receiving the incorrect treatment fol-
lowing randomisation. We refer to such errors as ‘ran-
domisation errors’. By considering how participants
affected by randomisation errors should be handled in
an ITT analysis, researchers can respond to these errors
when they are discovered in a way that will minimise
their impact on the analysis and the need to deviate
from ITT.
While randomisation errors are almost inevitable,
guidance on handling these errors is limited,14 and the
application of the ITT principle in this context has not
been considered to our knowledge. The aims of this
article are to (1) demonstrate the potential pitfalls of
attempting to correct randomisation errors and (2) pro-
vide guidance on handling common randomisation
errors when they are discovered. In developing our rec-
ommendations, we sought to maintain the goals of the
ITT principle by minimising the potential for bias in
the treatment effect estimate. In this article, we take the
ITT principle to mean that all randomised participants
are included in the analysis in their randomised group.
Examples of randomisation errors are drawn from our
experiences as trial statisticians, investigators and mem-
bers of independent data monitoring committees
involved mainly with publicly funded randomised trials
in health-related disciplines.
In what follows, we make several assumptions
about the underlying trial and randomisation process.
First, all participants are assigned a unique identifier
(a study ID), and a corresponding treatment group
during randomisation. Second, this information is
stored in an electronic randomisation record along
with the date and time of randomisation, and any
baseline variables used in the randomisation process.
Third, the errors occur in the implementation of the
randomisation schedule, rather than its design.
Fourth, the randomisation process is automated using
a computer or telephone randomisation service.
Manual randomisation processes are prone to addi-
tional problems15,16 that are not considered here.
Finally, the primary purpose of the trial is to assess
the superiority of an intervention, and hence, an ITT
analysis is of interest.
Methods and results
Potential pitfalls of attempting to correct
randomisation errors
Requests for randomisation errors to be ‘fixed’, by
removing any record of the incorrect randomisation
and proceeding as if it never occurred for example, are
common in our experience. Although these requests
may seem sensible, attempts to fix randomisation errors
often make the problem worse.14 We provide two case
studies that demonstrate the potential pitfalls of trying
to correct randomisation errors and make general rec-
ommendations regarding such corrections. Guidance
on handling specific randomisation errors is given later
in this article.
Case study 1. In a placebo controlled trial, consenting
participants were assigned the next available study ID
and corresponding treatment allocation from the ran-
domisation schedule and issued a bottle pre-labelled
with their study ID that contained either active or inac-
tive capsules, as appropriate. A participant assigned
study ID 3113 was mistakenly given the bottle labelled
3133. The error was discovered several weeks after
treatment had commenced, when a new participant was
assigned study ID 3133 and the corresponding bottle
could not be located. A staff member attempted to fix
the error by giving the second participant the bottle
labelled 3113. Unfortunately, the affected study IDs
were associated with different treatment allocations and
the switching of study IDs made the problem worse,
since both participants received the incorrect treatment.
Such crossover between treatment groups is proble-
matic, as it can reduce the estimated treatment effect
under an ITT analysis.2 Had the staff member reported
the error when it was discovered, a new bottle contain-
ing capsules from the correct treatment group could
have been prepared for the second participant, and only
the first participant would have received the incorrect
treatment.
Case study 2. In a blinded trial employing stratified ran-
domisation with randomly permuted blocks, a partici-
pant belonging to stratum A was incorrectly assigned
the next available study ID (8014) and corresponding
treatment group from stratum B. Before the participant
received any treatment, a staff member reported the
error and requested the incorrect randomisation be
undone by releasing study ID 8014 to be reassigned to
the next participant belonging to stratum B, allowing
the affected participant to be re-randomised correctly in
stratum A. By the time this request was received by the
coordinating centre, another participant had been
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randomised in stratum B. This raised questions about
what should be done with study ID 8014 if released as
suggested. Reallocating this ID to the next participant
randomised in stratum B would cause the randomisa-
tions in this stratum to become non-sequential, making
the randomisation records difficult to audit.
Conversely, skipping study ID 8014 would create a gap
in the randomisation schedule, interfering with the
blocking and potentially introducing imbalance in the
number of participants randomised to each group. In
either case, a systematic deviation from the intended
randomisation sequence would occur, which was
deemed unlikely to introduce bias but could harm trial
credibility. Had the trial been open-label, reallocating
study ID 8014 would have been even more problematic
due to the lack of allocation concealment following the
initial randomisation. Fortunately, the trial investiga-
tors decided to maintain the initial randomisation for
the participant, thus avoiding any further problems due
to the initial error.
General recommendations. While it may be possible to fix
randomisation errors by undoing the incorrect rando-
misation, especially if discovered and reported immedi-
ately, we caution against this for several reasons. First,
our case studies clearly demonstrate the potential for
corrections to cause further problems. Second, attempt-
ing to correct randomisation errors often violates the
ITT principle, since all randomised participants should
be analysed according to their initial randomisation,
whether or not the randomisation was performed as
intended. Finally, allowing randomisation errors to be
undone introduces the possibility of selection bias, since
participants assigned to the less favourable treatment in
an open-label trial, or responding poorly in a blinded
trial, may be examined more closely for randomisation
errors due to desire for reallocation. We therefore agree
with previous recommendations to document but not
correct randomisation errors,14 as this is the safest
approach and is most consistent with the ITT principle.
Guidance on handling common randomisation errors
when discovered
Responding to randomisation errors can be challenging.
General recommendations, such as documenting but
not correcting randomisation errors, can help guide
responses. However, the statistical, clinical, ethical and
practical issues associated with the error should be con-
sidered before an appropriate course of action is chosen,
and compromises are often required. We provide recom-
mendations for handling common randomisation errors
when they are discovered, as summarised in Table 1.
Participant randomised using incorrect baseline information.
Stratified randomisation or minimisation is often used
to ensure treatment groups are balanced with respect to
specific baseline variables that strongly influence the
outcome.17 These approaches may fail to achieve bal-
ance if randomisations are performed using incorrect
baseline information. An example of this was seen in
case study 2 and there are several reasons why such
errors occur. First, the researcher randomising the par-
ticipant may receive incorrect baseline information.
This was seen in a trial stratified by use of dietary sup-
plements containing a specific nutrient of interest,
where a participant was classified in the wrong stratum
after providing the incorrect name for the dietary sup-
plement they had been taking. Second, the researcher
may have access to the correct baseline information but
enter it incorrectly into the randomisation service. This
occurred in a trial stratified by age, where the date of
birth was incorrectly entered for a participant and
their automatically calculated age placed them in the
incorrect stratum. Baseline information errors may be
recognised immediately or discovered later through
Table 1. Summary of recommendations for handling common randomisation errors when they are discovered.
Randomisation error Recommendations
Participant randomised using incorrect baseline
information.
Accept the randomisation but record the correct baseline information.
Ineligible participant randomised. Keep the participant in the trial and collect all relevant data, unless an unbiased
process for excluding ineligible participants has been pre-specified. Seek clinical
input to determine their appropriate management.
Participant randomised multiple times:
(a) Only one set of baseline and outcome data
will be obtained.
(b) Multiple sets of baseline and outcome data
will be obtained.
(a) Retain the initial randomisation and disregard the second randomisation.
(b) Retain both randomisations, unless an unbiased process for excluding the
second randomisation has been pre-specified.
Participant received incorrect treatment. Record the treatment the participant received and seek clinical input regarding
their ongoing treatment.
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reviewing the randomisation records and cross-
checking against an alternate data source.
When participants are randomised according to
incorrect baseline information, under the ITT principle
they should be analysed in their allocated treatment
group, irrespective of the fact that their allocation was
based on incorrect information. We therefore recom-
mend that the initial randomisation is accepted and the
participant is treated according to their group alloca-
tion, rather than re-randomised. The incorrect baseline
information should be kept in the randomisation
record, as this reflects how the randomisation was actu-
ally performed,14 and the correct information docu-
mented for use in an adjusted analysis.18,19
Ineligible participant randomised. Participants should only
be randomised once their eligibility has been con-
firmed. Unfortunately, even in the presence of clear
inclusion and exclusion criteria, it is not unusual for
ineligible participants to be inadvertently randomised.
This may result from trial staff receiving inaccurate or
incomplete information about potential recruits, or fail-
ing to correctly apply all inclusion and exclusion cri-
teria. For example, in a trial enrolling extremely
preterm infants, a staff member randomised an ineligi-
ble infant after incorrectly calculating their gestational
age. Participant ineligibility can be difficult to detect
following randomisation, but may be discovered
through cross-checking the baseline information
against an alternate source or through further examina-
tion of randomised participants.
If a randomised participant is found to be ineligible,
a decision needs to be made regarding their ongoing
management. The allocated treatment must be withheld
or stopped if the reason for ineligibility means that
commencing or continuing treatment is inappropriate,
suboptimal or potentially unsafe. For example, a parti-
cipant with high baseline potassium levels was inadver-
tently randomised into a trial where the intervention
was contraindicated for such individuals, and hence
treatment was ceased when their ineligibility was dis-
covered. In other scenarios, it may be problematic to
cease treatment based on personal or clinical reasons.
We advocate seeking clinical input when making such
decisions.
Whether participants should remain in the trial once
their ineligibility is discovered depends on whether they
should contribute to the ITT analysis, which is a matter
of some debate. While standard application of the ITT
principle requires that all randomised participants are
included in the analysis, regardless of eligibility, it is
possible to exclude ineligible participants from the anal-
ysis without biasing the treatment group comparison if
the reason for and discovery of the ineligibility is inde-
pendent of treatment group and outcome. For example,
bias is unlikely to be introduced if ineligible participants
are excluded by an independent panel, blinded to treat-
ment group, who review eligibility for all participants
based on their status before randomisation.1,2,20 If
exclusions cannot be made in an objective and unbiased
manner, then ineligible participants should be included
in the analysis.20 We therefore recommend that ineligi-
ble participants who are incorrectly randomised remain
in the trial and have all relevant data collected, unless
an unbiased process for excluding ineligible participants
from the analysis has been pre-specified, in which case
they may be withdrawn. However, we recognise that
following this recommendation may not always be
appropriate. For example, when a randomised partici-
pant was deemed ineligible because they had not pro-
vided informed consent, they could not ethically remain
in the trial and were thus withdrawn. When ineligible
participants are withdrawn, we propose keeping their
randomisation record for auditing purposes and noting
the reason for the withdrawal.
Participant randomised multiple times. In some trials, parti-
cipants can legitimately be randomised multiple times.
For example, in pregnancy trials with long recruitment
periods, women may be eligible to participate during
more than one pregnancy. More commonly, only a sin-
gle randomisation is allowed per participant and multi-
ple randomisations constitute a randomisation error.
Such errors can arise unintentionally or deliberately
due to a perceived problem with the initial
randomisation.
When the second randomisation is performed in
close succession to the first (on the same day for exam-
ple), the affected participant typically only has one set
of baseline and outcome data, and only receives one
treatment. The ITT principle suggests that the affected
participant should be analysed in the treatment group
assigned during the first randomisation, independent of
any subsequent randomisations that occurred in error.
We thus propose that participants incorrectly rando-
mised multiple times in close succession retain the study
ID and receive the treatment allocated during the initial
randomisation. The second randomisation can then be
disregarded and the reason documented, but the rando-
misation record should be kept. This approach allows
the affected participant to be included in the analysis
according to the first randomisation, which means that
all randomised participants can be analysed, in keeping
with the ITT principle. Importantly, exclusion of the
second randomisation from the analysis is not expected
to introduce bias into the treatment effect estimate, pro-
vided its discovery is uninfluenced by treatment alloca-
tion or outcome. This can be achieved by checking
whether any trial participants have the same identifying
information. Failure to exclude the second randomisa-
tion would result in some participants being included in
the analysis twice with the same data, potentially under
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different randomised groups, which would artificially
inflate the sample size.
When there is a substantial time delay between mul-
tiple randomisations for the same participant, they may
have different baseline or outcome data recorded under
each randomisation, and may receive multiple treat-
ments. Since the affected participant is actually ineligi-
ble at the time of the second randomisation,
recommendations provided for handling ineligible par-
ticipants can be applied to the second randomisation
(i.e. it should only be excluded based on a pre-specified
unbiased process), although additional complexities
arise here. First, the participant may have already
received some treatment under the first randomisation
and this could influence decisions regarding their
ongoing management. Second, if it is decided that no
exclusions will be made during the analysis because of
the potential for introducing bias, the non-
independence of observations arising from repeated
participation in the trial should be considered.
Participant received incorrect treatment. Treatment issuing
errors can arise when the treatment information pro-
vided at the time of randomisation is misread or misin-
terpreted. In addition to case study 1, this occurred in
an open-label trial comparing a device intended to
assist patients with a particular medical condition to no
device, when a participant received the device after a
researcher misread their treatment assignment. These
errors may be discovered by cross-checking the rando-
misation records with the documented treatment
received or during product inventory. Treatment issu-
ing errors also occur when the assigned treatment is
not available, as sometimes occurs in drug trials when
the drug pack labelled with the assigned number cannot
be located. These errors would typically be identified
immediately.
When treatment issuing errors are discovered, a deci-
sion must be made regarding the ongoing treatment of
the participant. In a standard ITT analysis, participants
will be analysed as part of the allocated treatment
group, independent of the treatment they received.
Since any treatment effect is diluted when participants
receive the incorrect treatment,2 participants would ide-
ally switch to the correct treatment when errors are dis-
covered. However, the appropriate course of action
depends on how soon the error is discovered, the nature
and intended duration of the treatment, whether switch-
ing treatments is feasible, and the clinical implications
of switching treatments, such as whether a washout
period is required. Changing treatments may lead to
confusion for the participant and is often inappropriate,
for example in surgical trials where the error is discov-
ered after another operation has been performed.
Continuing with the incorrect treatment is often the
safest and simplest approach. When treatment issuing
errors are discovered, we recommend seeking clinical
input before making decisions regarding the ongoing
treatment of the participant. In blinded trials, decisions
should be made blinded to the allocated treatment
group to preserve the integrity of the blinding. While no
changes should be made to the assigned treatment
group in the randomisation record, the treatment the
participant actually received should be documented.
Discussion
We have discussed errors that commonly occur during
the randomisation process and provided recommenda-
tions on how they should be handled when discovered.
In general, we believe the safest option is to accept the
randomisation errors that do occur and leave the initial
randomisation records unchanged. This approach is
consistent with the ITT principle, since it enables parti-
cipants to be analysed as randomised, and avoids fur-
ther problems that can arise when attempts are made to
correct randomisation errors. A potential disadvantage
of accepting randomisation errors is that imbalance
could be introduced between the randomised groups in
the number of participants or their baseline characteris-
tics. However, any imbalance due to randomisation
errors is expected to be minimal unless errors are com-
mon. Imbalance can be monitored by an independent
data monitoring committee during the trial and investi-
gated by the trial statistician at the analysis stage.
Prevention of randomisation errors is important for
maintaining trial quality. Strategies for preventing
errors include thoroughly testing the randomisation
service before the trial commences; reviewing and con-
firming the information entered into the randomisation
service before each randomisation is performed; speci-
fying clear and simple eligibility criteria and recruit-
ment processes; and requiring two staff members to
check the treatment allocation or blinded treatment
code before any treatment is issued. Unfortunately,
avoiding randomisation errors altogether is often
impossible. Individuals responsible for randomising
participants should therefore be well trained in all
aspects of the randomisation process, including the
actions to be taken when errors occur. Randomisation
errors should be reported as soon as they are discov-
ered so the details can be documented and the appro-
priate course of action determined. Decisions regarding
errors are best made in consultation with the trial sta-
tistician, who can assess the implications of the pro-
posed course of action for the analysis.
While randomisation errors are occasionally docu-
mented in trial publications,21–24 there is currently little
incentive for researchers to report these errors, since it
is not a requirement in the widely adopted
Consolidated Standards of Reporting Trials
(CONSORT) statement.11,25 We advocate reporting the
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number and type of randomisation errors that occurred
in the trial along with how they were handled, or stat-
ing that no randomisation errors were identified, as this
will assist readers to assess trial quality and the success
of the randomisation. This practice could be encour-
aged by including randomisation errors in a future
update of the CONSORT statement.
In conclusion, randomisation errors are not uncom-
mon and deserve greater attention in the literature. We
hope this article has raised awareness of the types of
randomisation errors that can occur and provided use-
ful guidance on dealing with such errors when they are
discovered. We encourage researchers to consider the
ITT principle when deciding how to handle randomisa-
tion errors in their trials.
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